Bright Minds Biosciences

About:

Bright Minds Biosciences is a biotech company that engages in the development of serotonergic therapeutics to treat mental health disorders.

Website: https://brightmindsbio.com/

Twitter/X: brightmindsbio

Top Investors: PsyMed Ventures

Description:

Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Total Funding Amount:

$63.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Vancouver, British Columbia, Canada

Founded Date:

2017-11-01

Contact Email:

info(AT)brightmindsbio.com

Founders:

Alan P. Kozikowski, Gideon Shapiro, Ian Macdonald

Number of Employees:

11-50

Last Funding Date:

2024-10-18

IPO Status:

Public

Industries:

© 2025 bioDAO.ai